Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cicloprolol SCHEMBL9681296 | 1.00 | ADRB1 (0.80) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL634972 | 1.00 | ADRB1 (0.80) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL613271 | 0.99 | LMNA (0.81) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL22734881 | 0.99 | LMNA (0.81) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Cicloprolol SCHEMBL613272 | 0.98 | ADRB1 (0.77) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| SCHEMBL11247586 | 0.96 | ADRB1 (0.75) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Betaxolol SCHEMBL23531 | 0.89 | ADRB1 (1.00) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Betaxolol SCHEMBL4997902 | 0.89 | ADRB1 (1.00) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Levobetaxolol SCHEMBL23532 | 0.89 | ADRB1 (1.00) | ADRB1LMNAMEN1KMT2ACYP2D6 | |
| Betaxolol SCHEMBL6512495 | 0.89 | ADRB1 (1.00) | ADRB1LMNAMEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0498705-A1 | Phenol ethers derivatives, their preparation and their therapeutical use | SYNTHELABO (FR) | 1992-08-12 | — | — | EP | claimed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-0498705-A1 | Phenol ethers derivatives, their preparation and their therapeutical use | SYNTHELABO (FR) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607458-B2 | Enrichment-triggered chemical delivery system | HMGB1, PAICS, CCL2 | ADRB1 3761/4885LMNA 1843/4885MEN1 1575/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ADRB1 281/4885LMNA 2176/4885MEN1 2694/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ADRB1 281/4885LMNA 2176/4885MEN1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.